Azilect tablets are taken by mouth for Parkinson’s disease. Rasagiline helps preserve dopamine signalling in the brain.
They contain rasagiline mesylate, a selective monoamine oxidase-B inhibitor used alone in early disease or alongside levodopa when motor symptoms fluctuate.
The dose and frequency of Azilect depend on the purpose of treatment and are agreed with a doctor or pharmacist. The route is oral, and the tablets are taken as part of a regular Parkinson’s regimen.
Key administration principles include:
The intended regimen may differ when Azilect is used alone compared with add-on treatment. Other medicines can also change the safety of MAO-B inhibition. For this reason, the dose cannot be selected from symptom severity alone.
A tablet should not be crushed, split, or altered unless the prescriber or dispensing pharmacist confirms that the specific tablet can be handled that way. Altering an oral medicine can create swallowing problems or make administration less reliable.
Azilect contains rasagiline mesylate, a propargylamine compound in the indane chemical class. Rasagiline belongs to the monoamine oxidase inhibitor group and is used to manage Parkinson’s disease in adults. Its role is to support dopaminergic signalling when the brain’s dopamine-producing pathways become impaired.
The active substance is designed to inhibit monoamine oxidase-B, an enzyme involved in dopamine breakdown. Canadian and European prescribing information classifies rasagiline as a selective MAO-B inhibitor for Parkinson’s disease treatment [1].
Azilect is used in two main treatment settings:
Rasagiline mesylate is the salt form used in the tablet. The pharmacologically active component is rasagiline, which acts on MAO-B in the central nervous system.
Rasagiline is a propargylamine derivative. The propargylamine portion contributes to its interaction with monoamine oxidase-B, while its indane structure distinguishes it chemically from several other Parkinson’s medicines.
This chemical detail matters clinically because rasagiline acts differently from levodopa and dopamine agonists. Levodopa supplies a dopamine precursor. Rasagiline reduces enzymatic dopamine breakdown. These approaches can be combined when one treatment does not provide adequate control.
Parkinson’s disease involves progressive dysfunction and loss of dopamine-producing neurons in the substantia nigra. Reduced dopamine transmission affects the circuits responsible for starting and controlling movement. Common motor consequences include slowness, rigidity, tremor, reduced stride length, and difficulty turning.
Rasagiline inhibits MAO-B in the brain. MAO-B normally contributes to dopamine metabolism. By reducing this breakdown, rasagiline can increase the amount of dopamine available for signalling in surviving dopaminergic pathways.
The inhibition is described as irreversible at the enzyme level. New enzyme activity depends on the body producing new MAO-B molecules, so the pharmacological effect lasts beyond the time rasagiline remains measurable in the bloodstream.
Rasagiline does not replace lost neurons. It also does not reverse the underlying neurodegenerative process. Its clinical purpose is symptom management and improved motor control, either alone or with levodopa. The FDA prescribing information describes its use for Parkinson’s disease as monotherapy or adjunctive therapy with levodopa [2].
Patients may notice better movement initiation or longer periods of useful mobility. The response varies with disease stage, levodopa schedule, sleep, falls, cognitive symptoms, and other medicines.
Azilect may be prescribed with levodopa when Parkinson’s symptoms return before the next levodopa dose. This pattern is called wearing-off. By supporting dopamine availability between levodopa doses, rasagiline may help extend useful movement time in selected patients.
Levodopa remains the most potent medicine for improving many Parkinson’s motor symptoms. Carbidopa is commonly combined with levodopa to reduce peripheral conversion of levodopa before it reaches the brain. Some treatment plans also use combination levodopa products such as Stalevo.
Several practical errors can reduce benefit or create avoidable risk:
One subtle mistake is judging treatment only by tremor. A person may have less freezing or longer walking periods without seeing a major change in tremor. Functional notes provide a better basis for adjustment.
Another is taking medicines at irregular times on busy mornings. Even when the total number of tablets is unchanged, inconsistent timing can make motor fluctuations harder to interpret.
Specific situations requiring medical review include:
Combining rasagiline with interacting medicines may increase the risk of serotonin toxicity, excessive blood pressure changes, confusion, agitation, or other serious reactions. The Canadian product information and Health Canada safety principles support a full medication review before treatment begins [3].
Do not start an antidepressant, cough medicine, opioid painkiller, or herbal mood product while taking Azilect without checking the combination. A short course can still matter.
Azilect is not suitable for everyone. This medication is not for you if you have a known allergy to rasagiline or any tablet ingredient, or if a prescriber has identified a contraindication based on your medicines or medical history.
Rasagiline can cause adverse effects, although not every person experiences them. Reported reactions include headache, nausea, abdominal discomfort, dry mouth, dizziness, falls, joint pain, and flu-like symptoms. When Azilect is combined with levodopa, dyskinesia may become more noticeable because dopaminergic activity increases.
Possible effects that need prompt medical attention include:
Impulse-control symptoms can be easy to miss because the person may initially experience them as increased motivation or confidence. Family members sometimes notice the change first. This is a medication-related clinical issue, not a character judgement.
Dyskinesia may appear as twisting, writhing, rocking, or irregular movements. It can reflect the combined dopaminergic effect of Azilect and levodopa rather than a simple worsening of Parkinson’s disease. The treatment plan may need adjustment.
Azilect may also contribute to orthostatic hypotension, meaning blood pressure falls after standing. Rising slowly, pausing at the bedside, and reporting repeated light-headedness can reduce fall risk while the regimen is assessed.
Rasagiline and selegiline are both MAO-B inhibitors used in Parkinson’s disease. They share a broad pharmacological purpose, yet their chemical structures, metabolism, formulations, and interaction profiles differ.
| Medicine | Pharmacological role | Practical distinction |
|---|---|---|
| Rasagiline | Selective MAO-B inhibitor | Oral tablet used alone or with levodopa |
| Selegiline | MAO-B inhibitor | Available in different formulations and may have different metabolism-related considerations |
| Safinamide | Selective MAO-B inhibitor with additional glutamate-related activity | Used in selected patients as add-on therapy |
Selegiline is associated with amphetamine-related metabolites, which can influence tolerability in some patients. Rasagiline does not share that exact metabolic profile. Safinamide has a different pharmacological profile and is generally considered in specific add-on treatment situations.
The choice depends on the patient’s motor pattern, levodopa response, sleep quality, hallucination risk, blood pressure, other medicines, and clinician experience. No MAO-B inhibitor is automatically the best option for every person.
One common mistake is treating MAO-B inhibitors as interchangeable. They are not interchangeable tablet-for-tablet. A switch requires a planned regimen because interaction restrictions and washout periods may apply.
In clinical practice, physicians usually assess Azilect by asking what the patient can do for longer or more reliably. Walking across a room, turning in bed, using cutlery, getting dressed, and reducing end-of-dose freezing are practical treatment outcomes.
A neurologist would also ask about sleep attacks, hallucinations, dizziness, falls, dyskinesia, and new impulsive behaviour. A medicine that improves movement but causes dangerous daytime sleepiness may require a different balance.
Treatment response is not always immediate or dramatic. Parkinson’s symptoms fluctuate naturally, and expectations should be based on repeated observations rather than one day. The American Academy of Neurology and the Movement Disorder Society both emphasise individualised treatment decisions in Parkinson’s care.
Age alone does not determine whether Azilect can be used. Frailty, kidney and liver function, cognition, blood pressure, falls, and the complete medication list are more useful clinical considerations.
Pregnancy and breastfeeding require an individual risk assessment. The 2024 European Medicines Agency product information advises caution because human pregnancy and lactation data are limited. A prescriber should review the need for rasagiline, disease control, and alternative treatment before exposure occurs. Do not stop Parkinson’s treatment abruptly after discovering a pregnancy; contact the treating clinician promptly.
Azilect is commonly organised as a regular daily oral treatment, with the exact timing selected by the prescriber. The 2023 Health Canada information supports following the prescribed schedule rather than changing the time according to a single symptom episode. Morning dosing may be convenient for some people, while others need timing coordinated with levodopa or a daily routine. A consistent time makes missed doses easier to identify and motor patterns easier to assess.
Alcohol can worsen dizziness, impaired balance, sleepiness, and falls in people with Parkinson’s disease. The WHO’s 2022 Parkinson’s disease guidance emphasises fall prevention and attention to medicines that affect alertness and mobility. Alcohol may also make it harder to recognise whether drowsiness or unsteadiness comes from Azilect, levodopa, or the drink itself. Discuss alcohol use with the prescriber, especially when falls, low blood pressure, or daytime sleepiness are present.
Regular physical activity adapted to ability can support strength, balance, flexibility, and daily function. The Parkinson Study Group and movement-disorder specialists commonly use 2024 exercise guidance that includes walking practice, resistance work, balance exercises, and physiotherapy as part of care. Large changes in diet, dehydration, irregular sleep, and skipped meals can worsen fatigue or dizziness even when Azilect is unchanged. Exercise should be paced around falls risk, freezing, blood pressure symptoms, and the person’s established medication schedule.
Older adults may use rasagiline when the prescriber considers the full clinical picture. The 2024 EMA product information highlights the need to assess hallucinations, orthostatic hypotension, falls, cognition, liver function, and interacting medicines. Older people can be more sensitive to dizziness, confusion, and sleepiness, especially when several Parkinson’s medicines are combined. Starting or changing treatment should include a review of walking safety and support at home.
Dyskinesia can occur, especially when Azilect is added to levodopa and total dopaminergic activity increases. The 2019 FDA clinical information identifies dyskinesia among adverse reactions observed with adjunctive treatment. The movements may look like writhing, twisting, rocking, or uncontrolled fidgeting. Record when they occur in relation to each levodopa dose, because the prescriber may adjust the overall regimen rather than simply removing Azilect.
Provide a complete list of medicines and supplements, including antidepressants, opioid painkillers, cough products, sleep aids, and St John’s wort. The 2023 Health Canada information recommends attention to interaction risks involving MAO inhibition and medicines that affect serotonin or alertness. Mention liver disease, fainting, falls, hallucinations, impulse-control problems, severe daytime sleepiness, pregnancy plans, and breastfeeding. The prescriber can then decide whether Azilect fits the treatment plan and how it should be combined with other Parkinson’s medicines.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
St. Catharines, took Azilect at the prescribed dose with his existing Parkinson’s treatment for several weeks. He described smoother mornings and fewer pauses when walking, but mild nausea during the first days made breakfast difficult. The nausea settled without stopping treatment.
Kelowna, used Azilect at the prescribed dose as an add-on to levodopa for several weeks. He reported longer periods of useful movement after the adjustment, although dizziness when standing remained troublesome. Recording blood pressure and movement periods helped his clinician change the wider regimen.
Red Deer, took Azilect at the prescribed dose and found that Azilect did not remove every off period. After several weeks, he noticed better control on some days but also more involuntary movements after levodopa doses. The treatment plan required review rather than simply increasing Azilect.
